Investors Buy High Volume of Put Options on Mesoblast (NASDAQ:MESO)

Mesoblast Limited (NASDAQ:MESO - Get Free Report) was the target of some unusual options trading on Thursday. Stock traders acquired 3,838 put options on the company. This represents an increase of approximately 350% compared to the average daily volume of 852 put options.

Institutional Investors Weigh In On Mesoblast

Institutional investors have recently made changes to their positions in the stock. Pine Valley Investments Ltd Liability Co acquired a new position in Mesoblast in the 2nd quarter valued at about $80,000. Rathbones Group PLC purchased a new stake in shares of Mesoblast during the 2nd quarter worth approximately $95,000. XTX Topco Ltd purchased a new position in shares of Mesoblast in the 2nd quarter valued at $103,000. Marshall Wace LLP acquired a new stake in Mesoblast during the 2nd quarter worth $562,000. Finally, Lazari Capital Management Inc. lifted its position in Mesoblast by 6.6% in the second quarter. Lazari Capital Management Inc. now owns 53,467 shares of the company's stock valued at $364,000 after acquiring an additional 3,300 shares during the last quarter. 1.43% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently issued reports on MESO shares. Piper Sandler lifted their target price on shares of Mesoblast from $11.00 to $15.00 and gave the company an "overweight" rating in a research report on Thursday. Jefferies Financial Group raised Mesoblast from a "hold" rating to a "buy" rating in a research note on Thursday, August 29th. StockNews.com lowered Mesoblast from a "hold" rating to a "sell" rating in a report on Wednesday, September 4th. Maxim Group raised shares of Mesoblast from a "hold" rating to a "buy" rating and set a $12.00 price objective for the company in a research note on Tuesday, September 24th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Mesoblast in a research report on Thursday, August 29th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to data from MarketBeat, Mesoblast presently has a consensus rating of "Moderate Buy" and an average target price of $13.50.

Mesoblast Stock Up 36.8 %

Mesoblast stock traded up $4.51 during mid-day trading on Thursday, hitting $16.76. The company's stock had a trading volume of 3,970,174 shares, compared to its average volume of 736,472. Mesoblast has a 1 year low of $1.61 and a 1 year high of $19.15. The stock's fifty day moving average is $10.24 and its two-hundred day moving average is $8.17. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.21.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.